Pioneering Differentiated TCR-T Therapies for Cancer Patients
Medigene is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Medigene was founded by scientists with the commitment to create breakthrough therapies to fundamentally improve the lives of cancer patients.
Medigene’s End-to-End Platform
The basis of Medigene’s differentiation is our End-to-End Platform of multiple, combinable, exclusive and proprietary technologies. These technologies have the potential to enhance our TCR-T drug products from a safety, durability and efficacy perspective as well as through optimizing our development processes at multiple sequential stages of development, from target screening, through TCR generation and optimization and ultimately into clinical development.
Generation & optimization
TCR-T Therapy armoring & enhancement
Manufacturing tCR-T Drug products
MDG1015: BRINGING OUR TCR THERAPIES TO PATIENTS
3rd generation NY-ESO-1 targeted TCR-T therapy combined with our PD1-41BB switch protein- a sensitive, specific TCR with a favorable safety profile
Our End-to-End Platform allows to develop highly innovative, complementary treatment options for various cancer types
Our TCR Technology
Our End-to-End Platform enables us to generate TCR-T cells with high sensitivity, specificity and safety